Zacks Research Begins Coverage on Fortress Biotech (NASDAQ:FBIO)

Equities research analysts at Zacks Research initiated coverage on shares of Fortress Biotech (NASDAQ:FBIO – Get Free Report) in a research note issued on Wednesday, Zacks reports. The firm set a “hold” rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also commented on the company. Wall Street Zen lowered Fortress Biotech from a “strong-buy” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss Ratings lowered shares of Fortress Biotech from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 23rd. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Fortress Biotech presently has an average rating of “Hold” and a consensus target price of $17.00.

Check Out Our Latest Stock Analysis on FBIO

Fortress Biotech Stock Down 5.7%

Shares of NASDAQ FBIO opened at $1.78 on Wednesday. The firm’s 50-day simple moving average is $2.07 and its 200 day simple moving average is $2.69. Fortress Biotech has a 12-month low of $1.64 and a 12-month high of $4.53. The company has a quick ratio of 3.83, a current ratio of 2.93 and a debt-to-equity ratio of 0.10. The company has a market cap of $60.16 million, a price-to-earnings ratio of 0.78 and a beta of 1.27.

Fortress Biotech (NASDAQ:FBIO – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.04. The business had revenue of $19.16 million for the quarter, compared to analyst estimates of $21.57 million. Fortress Biotech had a net margin of 143.04% and a return on equity of 61.84%. On average, research analysts expect that Fortress Biotech will post 2.66 earnings per share for the current fiscal year.

Insider Activity

In other Fortress Biotech news, CFO David Jin purchased 25,000 shares of the firm’s stock in a transaction on Wednesday, November 18th. The shares were acquired at an average cost of $1.91 per share, for a total transaction of $47,750.00. Following the completion of the transaction, the chief financial officer owned 1,692,761 shares of the company’s stock, valued at approximately $3,233,173.51. The trade was a 1.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Lindsay A. Md Rosenwald purchased 17,456 shares of the business’s stock in a transaction on Thursday, November 19th. The stock was acquired at an average price of $1.86 per share, with a total value of $32,468.16. Following the purchase, the chief executive officer directly owned 4,723,564 shares in the company, valued at $8,785,829.04. This represents a 0.37% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 184,328 shares of company stock worth $340,398 in the last three months. 28.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Marshall Wace LLP acquired a new stake in Fortress Biotech during the 3rd quarter worth about $462,000. Renaissance Technologies LLC increased its holdings in Fortress Biotech by 22.8% in the first quarter. Renaissance Technologies LLC now owns 99,590 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 18,490 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in Fortress Biotech in the second quarter valued at approximately $47,000. Institutional investors own 96.51% of the company’s stock.

Latest Fortress Biotech News

Investors following FBIO have been watching these news items:

  • Positive Sentiment: CEO Lindsay Rosenwald bought 136,723 shares across three transactions from November 17–19, spending about $253,000. CFO David Jin also bought 47,605 shares over the same period for approximately $88,000. These open-market purchases increased both executives’ holdings and may signal confidence in the company. CEO SEC filing CFO SEC filing
  • Neutral Sentiment: HC Wainwright forecast EPS of $2.66 for FY2026 and $2.37 for FY2027. The report also estimated a Q4 2026 loss of $0.15 per share; the articles did not provide a rating change or explain the basis for the annual forecasts. Analyst insights article

About Fortress Biotech

(Get Free Report)

Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company’s activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.

Featured Articles

Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.